ProCE Banner Series

A Year in Review: Experts Illuminate the Potential of ADCs Targeting HER2, HER3, and TROP-2 in NSCLC

Just us online for this live 90-minute, CME-certified webinar to hear from experts on the practical application of antibody‒drug conjugates targeting HER2, HER3, and TROP-2 for patients with NSCLC. During this dynamic webinar, you will have the opportunity to interact with the experts and ask questions at the end of the session. Register today!

To Register: Please click the green “Learn More” button below. On the next page, select “Register for Virtual Event.” Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AMA
Who Should Attend

This program is intended for physicians and other healthcare professionals caring for lung cancer patients.

All Events

A Year in Review: Experts Illuminate the Potential of ADCs Targeting HER2, HER3, and TROP-2 in NSCLC

Past Events

January

29

2024

1:30 PM - 3:00 PM Eastern Time (ET)

Virtual

Topics

  • Welcome and Introduction
  • Understanding the Implications of Targeting HER2, HER3, and TROP-2
  • Pathologic Testing and Interpretation
  • Analyzing and Applying the Latest Clinical Trial Data
  • ADC Therapies Addressing Unmet Needs in NSCLC
  • Combining ADC Therapies With Immuno-oncology and Other Targeted Agents
  • Strategies for Adverse Event Identification and Management
  • Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC) 

Target Audience
This program is intended for physicians and other healthcare professionals caring for lung cancer patients. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Provide a detailed understanding of the role HER2, HER3, and TROP-2, rationale for targeting with antibody-drug conjugates, and pathological considerations in NSCLC
  • Apply new data and evolving science specific to antibody-drug conjugates into clinical practice to expand treatment options and improve outcomes for patients with NSCLC malignancies
  • Plan individualized treatment strategies, incorporating novel HER2-, HER3-, or TROP-2–targeted antibody-drug conjugate combination strategies as appropriate, for patients with NSCLC
  • Develop individualized strategies involving the patient care team for the early identification and management of antibody-drug conjugate-associated adverse events

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.